The herbicide weiss is one of the world’s most potent chemicals and a widely used ingredient in cosmetics and other cosmetics.
Its patent expired in 2016 and its price has been frozen by the U.S. Patent and Trademark Office for more than two decades.
It is also a source of significant regulatory concern.
A few months ago, the U-S.
Food and Drug Administration granted the drug’s makers, Teva Pharmaceuticals and Novartis AG, permission to patent the chemical for use in cosmetics.
Teva’s lawyers said that the drug, sold under the brand name Weiss, was a safe, effective and nontoxic alternative to other products, such as the drug weiss, as well as other medications that are also used for pain relief.
Tevas pharmaceutical lawyer said in a statement that “Weiss is a potent pain reliever, which is why it is often used in cosmetic formulations.”
The drug is a common ingredient in the world of cosmetics, but its use in drugs has been controversial.
In 2014, the FDA approved the use of Weiss for the treatment of osteoarthritis, but the agency also gave it a green light to be used in other medical applications.
But that green light has not yet been issued, and a federal judge recently rejected a lawsuit by the American Society of Dermatology and the American Academy of Dermicology.
In November, the court ruled that the agency lacked the authority to issue a green-light approval because the drug is not a drug and the FDA lacked the power to regulate its use.
The case is being argued in federal court in Los Angeles.
The case is Teva and Weiss v.
US Patent and Trade Office et al., No. 15-1615-cv-04608 (PDF).
A third company, Procter & Gamble Co., which sells the cosmetics brand Proctercare, was also sued by Teva.
The U.K.-based company sued Teva in September 2015.
Tevanos attorneys have argued that the companies’ drug is less potent than Weiss and therefore should not be considered for approval.
A jury will decide whether to grant the drug company’s patent application on Jan. 12.
Last year, the United States Court of Appeals for the Federal Circuit ruled in favor of the plaintiffs.
The court held that the FDA had no authority to grant Teva its green-lighting for use of the drug.
In a statement, the agency said it would defend Teva vigorously.
“The Teva company has made a strong and convincing case that the Teva brand Weiss is safe, inexpensive, nontoxic, effective, and has no harmful side effects,” said David M. Kocher, the acting administrator for the FDA.
“In support of that claim, the company also submitted evidence that Teva has made significant progress in advancing the safety and efficacy of its Weiss formulation.”
In an e-mailed statement, Tevas lawyer David Mott said, “We’re disappointed that the courts have rejected our case, but we will continue to fight tooth and nail to make sure Teva gets the green light for its products.”
The agency said that in a separate lawsuit Teva was challenging the FDA’s authority to regulate the drug in the face of a 2014 ruling that the product should be allowed for sale.
In that case, the federal appeals court said the FDA was the sole regulator of Weis pharmaceutical products.
On Monday, the appeals court rejected Tevas request to dismiss the lawsuit on the grounds that the DEA has no authority under its oversight.
As part of its request, Tevanas lawyers argued that FDA should have the authority over Teva because the agency is an agency that regulates drug development and manufacturing.
Tevinas lawyers said the agency lacks the authority and the duty to protect the public from harm when it issues its own safety and effectiveness certification.
Teva said it will appeal the decision and will seek the U .
Court of Federal Claims to reinstate its lawsuit against Teva, saying it has done nothing wrong.
This article is part of USA TODAY’s continuing coverage of the U.-S.